Belujon Pauline, Grace Anthony A
INSERM, U1084, Poitiers, France; University of Poitiers, U1084, Poitiers, France.
Departments of Neuroscience, Psychiatry and Psychology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Int J Neuropsychopharmacol. 2017 Dec 1;20(12):1036-1046. doi: 10.1093/ijnp/pyx056.
Anhedonia is considered a core feature of major depressive disorder, and the dopamine system plays a pivotal role in the hedonic deficits described in this disorder. Dopaminergic activity is complex and under the regulation of multiple brain structures, including the ventral subiculum of the hippocampus and the basolateral amygdala. Whereas basic and clinical studies demonstrate deficits of the dopaminergic system in depression, the origin of these deficits likely lies in dysregulation of its regulatory afferent circuits. This review explores the current information regarding the afferent modulation of the dopaminergic system and its relevance to major depressive disorder, as well as some of the system-level effects of novel antidepressants such as agomelatine and ketamine.
快感缺失被认为是重度抑郁症的核心特征,多巴胺系统在该疾病所描述的享乐缺陷中起关键作用。多巴胺能活动复杂,受包括海马体腹侧下托和基底外侧杏仁核在内的多个脑结构调节。尽管基础研究和临床研究表明抑郁症患者存在多巴胺能系统缺陷,但这些缺陷的根源可能在于其调节传入回路的失调。本文综述探讨了有关多巴胺能系统传入调节及其与重度抑郁症相关性的现有信息,以及阿戈美拉汀和氯胺酮等新型抗抑郁药的一些系统水平效应。